Christoph Wanner

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L.J. Visseren, François Mach, Yvo M. Smulders et al. · European Heart Journal · 2021 · 6.3K citations · Full text

Medicine, Cardiology, Preventive Medicine +15

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer, Stefan D. Anker, Javed Butler et al. · New England Journal of Medicine · 2020 · 5K citations · Full text

Medicine, Cardiology, Pharmacology +17

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström et al. · Journal of Hypertension · 2023 · 3.1K citations · Full text

Medicine, Cardiology, Internal Medicine +17